Pradaxa lawsuits blame the blood thinner for serious injuries, including uncontrollable bleeding. Boehringer Ingelheim Pharmaceuticals faces more than 2,400 Pradaxa lawsuits in state court. The first two cases went to trial in March and May 2018. Two more trials are set for September 2018 and February 2019. Lawyers continue to file Pradaxa lawsuits. Boehringer Ingelheim settled more than 4,100 Pradaxa lawsuits in 2014. The company said it would pay $650 million to resolve the cases pending at the time.
*Update: Pradaxa lawsuits started going to trial in 2018. The last of four scheduled trials is set to start in February 2019. The outcome of the trials can affect the more than 2,400 Pradaxa lawsuits still pending in state court. Pradaxa lawyers continue to accept new cases.
Pradaxa lawsuits blame the drug for thousands of injuries and hundreds of deaths. Affected patients and their surviving family members are suing the drug’s maker, Boehringer Ingelheim.
Pradaxa lawyers are filing lawsuits in state court in Connecticut. Boehringer Ingelheim Pharmaceuticals’ U.S. headquarters is in that state.
The Connecticut courts have consolidated the cases into a complex litigation. Claims in the Connecticut lawsuits are similar or identical to thousands of Pradaxa lawsuits settled in 2014. Many of the current cases involve injuries that happened after the $650 million settlement.
The blood thinner Pradaxa is linked to dangerous side effects, including uncontrollable bleeding. Marketing campaigns pushed the idea that Pradaxa was easy to take and didn’t require monitoring. But internal company documents showed that employees tried to quash a research paper. They feared it would lead to a blood test requirement.
In all, more than 6,500 people have filed Pradaxa lawsuits against Boehringer Ingelheim.
The first Pradaxa trials are underway in Connecticut. These so-called bellwether trials can give the parties an idea of how the rest of the cases may proceed.
The first two bellwether trials concluded in March and May 2018. Both yielded jury verdicts in favor of Boehringer Ingelheim. The next two trials are set for September 2018 and February 2019.
Mary Boone’s estate filed the first case to go to trial. Boone died on March 24, 2014, from an uncontrolled gastrointestinal bleed. Her doctor prescribed Pradaxa to lower her risk of stroke from atrial fibrillation.
Boehringer Ingelheim argued in court documents that the drug’s warnings were adequate. The company maintained that Boone’s doctor understood the risks.
On March 23, 2018, jurors handed up a verdict siding with the drug company.
The second bellwether trial involved Mary Lou Gallam’s lawsuit. Gallam’s doctor prescribed Pradaxa for atrial fibrillation in 2011. She suffered a “major bleeding event” on April 9, 2014, according to court filings.
On May 7, 2018, jurors in the Gallam case handed up their verdict in favor of Boehringer Ingelheim.
People are filing Pradaxa lawsuits because they blame the drug for uncontrollable bleeding and death.
The U.S. Food and Drug Administration approved Pradaxa in 2010. More than 540 people who took Pradaxa died in 2011. Thousands of other people reported suffering from serious side effects that year.
Emergency room doctors and trauma surgeons reported patients suffering life-threatening bleeding that was difficult to reverse. Boehringer Ingelheim sold Pradaxa for five years without a bleeding remedy.
An important step to file a Pradaxa lawsuit is to contact an experienced Pradaxa lawyer. Most qualified Pradaxa lawyers will review cases for no charge.
If a Pradaxa attorney concludes a consumer has a viable claim, the attorney can work with the consumer to file a personal injury or wrongful death lawsuit. Typically, Pradaxa lawyers don’t collect any fees until they win a case.
Pradaxa lawsuits say Boehringer Ingelheim developed a bleeding remedy in 2010. But the company didn’t seek approval for the remedy until Feb. 19, 2015. The FDA first approved Praxbind, a fast-acting Pradaxa antidote, in October 2015.
Pradaxa is only effective if dosed properly for individual patients. Lawsuits assert that there is no accurate test to check Pradaxa levels.
The lawsuits further claim Boehringer Ingelheim misled patients and their doctors about Pradaxa’s risks and benefits. Patients say Boehringer Ingelheim endangered the public through deceptive marketing practices. Lawsuits claim Pradaxa’s manufacturer did not adequately label the drug.
Boehringer Ingelheim announced a Pradaxa settlement plan on May 28, 2014. It said it would pay $650 million to settle 4,100 Pradaxa lawsuits that were pending at the time.
People are no longer able to file Pradaxa bleeding lawsuits in federal court as a result of the settlement.
Before the settlement, people filed thousands of Pradaxa lawsuits in federal court. A judicial panel consolidated most of the lawsuits into a multidistrict litigation (MDL).
MDLs allow a single judge to oversee the court proceedings for similar complex cases. A judge in the U.S. District Court for the Southern District of Illinois managed the Pradaxa MDL.
U.S. District Court Judge David Herndon planned to conduct four Pradaxa trials. The trials were to happen between August 2014 and February 2015.
Herndon selected the cases to help attorneys determine the effectiveness of their arguments. Two were wrongful death lawsuits. Two blamed Pradaxa for severe injuries.
But the trials never started. Boehringer Ingelheim settled the cases instead. Herndon closed the MDL in December 2017 after the last case was resolved.
There are no known Pradaxa class action lawsuits. Instead, Pradaxa lawyers are filing individual personal injury lawsuits.
Class action lawsuits represent large groups of individuals against the same defendants. Federal and state laws restrict these cases. They are not as common as many believe.
Instead, lawyers will file individual lawsuits. If a large number of people claim the same drug injured them, a judicial panel may group the cases.
On a federal level, this is multidistrict litigation. In state courts, it’s complex litigation.
Please seek the advice of a medical professional before making health care decisions.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(888) 645-1617